Assembly Biosciences Inc (ASMB)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
John G. McHutchison
Employees:
100
11711 N. MERIDIAN STREET, SUITE 310, CARMEL, IN 46032
(212) 554-4388

Assembly Biosciences, Inc. discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

Data derived from most recent annual or quarterly report
Market Cap 46.075 Million Shares Outstanding52.121 Million Avg 30-day Volume 104.646 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.32
Price to Revenue0.0 Debt to Equity0.0 EBITDA-83.198 Million
Price to Book Value1.0937 Operating Margin0.0 Enterprise Value268.101 Thousand
Current Ratio7.256 EPS Growth0.411 Quick Ratio6.814
1 Yr BETA 0.6058 52-week High/Low 1.79 / 0.77 Profit Margin0.0
Operating Cash Flow Growth8.9668 Free Cash Flow to Firm (FCFF) TTM -53.516 Million Free Cash Flow to Equity (FCFE) TTM-58.548 Million
Altman Z-Score-16.0274
Earnings Report2023-11-07
View SEC Filings from ASMB instead.

View recent insider trading info

Assembly Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ASMB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ASMB

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-09-18 by WHITE NICOLE S
  • 4: filed on 2023-08-03 by DELANEY WILLIAM E IV
  • 4: filed on 2023-08-03 by OKAZAKI JASON A
  • 4: filed on 2023-07-25 by BJORKQUIST JEANETTE M
  • 4: filed on 2023-06-23 by DELANEY WILLIAM E IV
  • 4: filed on 2023-06-23 by OKAZAKI JASON A
  • 4: filed on 2023-05-31 by DELANEY WILLIAM E IV
  • 4: filed on 2023-05-30 by MCHUTCHISON JOHN G
  • 4: filed on 2023-05-30 by MAHONY SUSAN
  • 4: filed on 2023-05-30 by JOHNSON-PRATT LISA

    • Events (8k)

  • 8-K: filed on 2023-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
  • 8-K: filed on 2023-05-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-18:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-22:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-15:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-19:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-23:
  • 144: filed on 2023-05-23:
  • 144: filed on 2023-05-23:
  • 144: filed on 2023-05-30:
  • 144: filed on 2023-08-02:
  • 144: filed on 2023-08-02:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    21.3 Thousand total shares from 2 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WHITE NICOLE S CHIEF MANUFACTURING OFFICER

    • Officer
    		 86,142 2023-09-13 1

    OKAZAKI JASON A CEO AND PRESIDENT

    • Officer
    • Director
    		 164,786 2023-08-02 6

    DELANEY WILLIAM E IV CHIEF SCIENTIFIC OFFICER

    • Officer
    		 142,744 2023-08-02 6

    BJORKQUIST JEANETTE M PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 26,688 2023-07-24 3

    ALTIG ANTHONY E

    • Director
    		 0 2023-05-25 1

    RINGO WILLIAM R

    • Director
    		 0 2023-05-25 1

    MAHONY SUSAN

    • Director
    		 0 2023-05-25 1

    CONSYLMAN GINA

    • Director
    		 0 2023-05-25 1

    MCHUTCHISON JOHN G

    • Director
    		 0 2023-05-25 3

    JOHNSON-PRATT LISA

    • Director
    		 0 2023-05-25 1

    HOUGHTON MICHAEL

    • Director
    		 0 2023-05-25 1

    SAMAR MICHAEL P. CHIEF FINANCIAL OFFICER

    • Officer
    		 77,228 2022-07-25 0

    DIMARCHI RICHARD D

    • Director
    		 20,000 2022-05-25 0

    STAMM LUISA M CHIEF MEDICAL OFFICER

    • Officer
    		 194,168 2022-03-29 0

    HOLUBIAK MYRON Z

    • Director
    		 15,000 2021-05-20 0

    RUSSO THOMAS JOSEPH CFO

    • Officer
    		 122,133 2021-03-29 0

    PAPKOFF JACQUELINE SYBIL SVP-CSO MICROBIOME

    • Officer
    		 37,364 2020-12-14 0

    LEWIS ALAN

    • Director
    		 0 2020-06-11 0

    KIM HELEN SUSAN

    • Director
    		 0 2020-06-11 0

    COLONNO RICHARD JAMES EVP & CSO, VIROLOGY OPS

    • Officer
    		 137,009 2020-03-27 0

    SMALL DEREK A

    • Director
    		 828,791 2020-01-02 0

    AUERBACH MARK

    • Director
    		 0 2019-05-17 0

    COOPER GRAHAM K SEE REMARKS

    • Officer
    		 117,500 2019-03-29 0

    LOPATIN URI A CHIEF MEDICAL OFFICER

    • Officer
    		 632,361 2019-03-29 0

    ECOR1 CAPITAL FUND QUALIFIED, L.P.

    • 10% Owner
    		 0 2018-04-17 0

    ROLLINS THOMAS E CHIEF DEVELOPMENT OFFICER

    • Officer
    		 3,750 2018-03-29 0

    BARRETT DAVID JONATHAN SEE REMARKS

    • Officer
    		 0 2017-03-29 0

    BARBOSA MIGUEL SEE REMARKS

    • Officer
    		 0 2016-10-06 0

    ARNOLD LEE D CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2014-07-11 0

    ELLISON RUSSELL H CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 23,200 2014-07-10 0

    ZLOTNICK ADAM

    • 10% Owner
    		 1,321,009 2014-07-10 0

    FELDER JOSEPH

    • Director
    		 0 2013-03-06 0

    ROWLAND THOMAS ANDREW CHIEF BUSINESS OFFICER

    • Officer
    		 18,387 2012-01-15 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    OKAZAKI JASON A - Director - Officer CEO AND PRESIDENT

    		2023-08-03 16:05:27 -0400 2023-08-02 S 11,827 $1.09 d 164,786 direct -0.9091 -4.5455 -9.3636 0.0 1 -19.0909 12

    DELANEY WILLIAM E IV - Officer CHIEF SCIENTIFIC OFFICER

    		2023-08-03 16:10:09 -0400 2023-08-02 S 9,461 $1.09 d 142,744 direct -0.9091 -4.5455 -9.3636 0.0 1 -19.0909 12

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 22:15:05 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 21:45:03 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 21:15:04 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 20:45:04 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 20:15:05 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 19:45:03 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 19:15:04 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 18:45:04 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 18:15:04 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 17:45:03 UTC 0.0 0.0 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 17:15:03 UTC 0.0 0.0 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 16:45:04 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 16:15:05 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 15:45:04 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 15:15:03 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 14:45:03 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 14:15:03 UTC 4.826 0.494 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 13:45:03 UTC 4.8416 0.4784 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 13:15:05 UTC 4.8416 0.4784 1500000
    ASSEMBLY BIOSCIENCES INC ASMB 2023-09-27 12:45:05 UTC 4.8416 0.4784 1500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund ASMB -122.0 shares, $-1199.26 2019-09-30 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund ASMB -13.0 shares, $-192.79 2020-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ASMB -100.0 shares, $-115.0 2023-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments